A Revolutionary Paradigm Shift in Drug Development
Our nanotherapeutic platform is produced utilizing a patented electro-crystal-chemistry process that results in highly-faceted, clean-surfaced nanocrystals of pure transition elements.
Neuronal decline occurs as a part of natural aging. In neurodegenerative diseases like ALS, neuronal decline and energy deficits are amplified and exacerbated1. These energetic deficits result from and lead to neuronal dysfunction and death.
By transmitting thousands of energy-supportive electrons per second per nanocrystal, CNM-Au8® rapidly catalyzes NAD+. This catalytic reaction drives production of adenosine triphosphate (ATP), also known as the energy currency of the body.
Once inside cells, catalytically-active nanotherapeutics stimulate ATP production and utilization while reducing oxidative stress and lowering levels of misfolded proteins, which are harmful to human health.
This innovative platform can be applied to developing a wide range of nanotherapeutics with unique energy profiles, generating a pipeline of drug candidates with broad applicability across different diseases.
Our lead drug candidate, CNM-Au8, is an oral suspension of clean-surfaced, catalytically-active gold nanocrystals. Resulting from a number of patented manufacturing breakthroughs, CNM-Au8 is currently in development as a disease-modifying treatment for Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson’s Disease. There have been over 350 patient years of CNM-Au8 exposure without identified safety signals.
1Camandola, S. & Mattson, M. P. Brain metabolism in health, aging, and neurodegeneration. EMBO J 36, 1474–1492 (2017).